Discovery of New Antibiotics
against Carbapenem-Resistant
Gram-negative Bacteria

Mutabilis is a biopharmaceutical company developing ​ novel-class antibacterials to treat life-threatening infection caused by WHO Priority 1 / Critical pathogens:

  • Carbapenem-resistant Acinetobacter baumannii
  • Carbapenem-resistant Pseudomonas aeruginosa
  • Carbapenem-resistant Enterobacterales

We thank our past and present partners:


Wandrille Ract-Madoux
Chief Executive Officer

Graduated in 2000 from HEC, the leading French Business School, Wandrille started his career within M & A at JP Morgan, then became an entrepreneur. After 2 years at SG Capital Europe, a PE fund, he joined WCP, a mid-cap LBO fund upon its creation in 2005. In 2012, he joined POI, shareholder of Mutabilis, as CBO/CFO, and is today CEO of Mutabilis.   

François Moreau, PhD
Scientific Director

François has 25 years of experience in drug discovery. After 6 years at Pfizer in allergy and respiratory diseases, François joined Mutabilis in 2004 to explore the possibilities of inhibiting bacterial pathogenicity. Before focusing on discovery of Dabocins, he contributed to the development of a new class of antibacterials, the FabI inhibitors and a new class of antiretrovirals, the allosteric inhibitors of HIV integrase. François is co-author of 24 articles and co-inventor of 11 patents.

Sophie Chasset, PhD
Director of Chemistry

Sophie has more than 25 years of experience in medicinal chemistry. After 10 years at Cephalon, Sophie started to work on the promising diazabicyclooctane scaffold at Novexel in 2007, where she discovered improved Avibactam derivatives. Following the acquisition of Novexel by AstraZeneca in 2010, Sophie joined Mutabilis where she now heads Medicinal Chemistry, a team entirely dedicated to the discovery of Dabocins antibacterials. She co-authored 8 publications and 18 patents.